128 results about "Blood tumor" patented technology

The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies.The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN® (rituximab).

Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Also disclosed is a composition for preventing or treating blood tumor, which comprises a TIM-3 antibody as an active ingredient. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)), all of which are capable of expressing TIM-3. The diseases for which the therapeutic use is to be examined include blood diseases in which the expression of TIM-3 is observed in bone marrow or peripheral blood, particularly blood tumor.

The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN®.

A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering an needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood tumor cell count. If all of the foregoing steps are positive, the cancer is treated by applying imiquimod transdermally to rotating sites, preferably by mixing ALDARA® (imiquimod) 5% cream with an equal amount of H base cream; administering a vaccine containing tumor necrosis factor, preferably the BCG vaccine; and orally administering VALTREX® (valacyclovir) twice daily. The foregoing treatment method is also effective in treating Type I diabetes, MS, and other epidermal cancers.

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering a needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood tumor cell count. If all of the foregoing steps are positive, the cancer is treated by applying imiquimod transdermally to rotating sites, preferably by mixing ALDARA (TM) (imiquimod) 5% cream with an equal amount of H base cream (TM); administering a vaccine that induces production of tumor necrosis factor, preferably the BCG vaccine; and orally administering Valtrex (TM) (valacyclovir) twice daily. The foregoing treatment method is also effective in treating Type I diabetes, MS, and other epidermal cancers.

The invention discloses a human interleukin 2-polyethylene glycol conjugate as well as a preparation method and an application thereof. The human interleukin 2-polyethylene glycol conjugate comprisesrecombinant human interleukin 2 of at least one non-natural amino acid and PEG coupled to the at least one non-natural amino acid, the position of the at least one non-natural amino acid is selected from one or more sites of L36, M39, L40, M46, P47, L63, L66, E67, L70 and A73 corresponding to SEQ ID NO: 2, wherein the recombinant human interleukin 2 is a protein as shown in SEQ ID NO: 3 or a functional active fragment thereof. The human interleukin 2-polyethylene glycol conjugate provided by the invention can be used as a single drug or combined with an anti-tumor drug, and is used for treating solid tumors or blood tumors.

The present invention provides an antibody to human IL-3Rα chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3Rα chain but does not bind to C domain of the human IL-3Rα chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3Rα as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3Rα antibody as an active ingredient.

The invention discloses application of biphenol and / or derivatives thereof in preparation of drugs for inhibiting metastasis of cancer cells, wherein the biphenol is magnolol and / or honokiol. The cancer cells are one or a plurality kinds of cells from cells of brain tumor, blood tumor, esophageal cancer, liver cancer, skin cancer, prostate cancer, bone cancer, breast cancer and lung cancer. One novel application of the magnolol, the honokiol and derivatives of both are provided. The magnolol and the like can effectively inhibit cell adhesion, migration, invasion and expression of MMP-2, so that the magnolol and the like can effectively inhibit the metastasis of the cancer cells. The magnolol, the honokiol and the derivatives of both have low toxicity, almost no toxic and harmful effect on human normal cells, and good clinical anti-tumor application prospects.

The invention relates to a combined sorting purification device for circulating blood tumor cells. The device comprises a sorting structure, a purifying structure and a control structure, wherein guide wires of the control structure extend to connect the sorting structure and the purifying structure; the control structure controls the sorting structure and the purifying structure; the sorting structure comprises a micro-fluidic chip which comprises triangular micro-array columns on two sides and a wide channel between the micro-arrays; the purifying structure comprises a purifying chip, a permanent magnet, two stepping motors for supporting the permanent magnet to move and supporting pieces for supporting parts, the permanent magnet is arranged below the purifying chip, the two stepping motors are vertically arranged, and the permanent magnet is arranged on one of the stepping motors; the micro-fluidic chip is connected to the purifying chip through a tubular structure; the control structure comprises a power supply and a control unit; and the control structure controls the stepping motors to move. The device can sort and purify tumor cells effectively, and is simpler and more convenient.

The invention provides a medicine composition for treating tumors and an application thereof. The medicine composition is composed of acriflavine or pharmaceutically acceptable salts thereof, melphalan or pharmaceutically acceptable salts thereof, and a medicinal carrier, wherein the molar ratio of the acriflavine to the melphalan is 1:100 to 1:10, and the tumors comprise blood tumors and solid tumors. The forms of the medicine comprise single preparations prepared from acriflavine or melphalan respectively, or a compound preparation prepared from acriflavine and melphalan. The medicine composition provided by the invention has the effects of improving the curative effect on tumors, the toxicity of the medicine composition can be reduced, and the growth speeds of the tumors can be slowed down.

The invention discloses a blood tumor data acquisition and in-hospital and out-of-hospital integrated diagnosis and treatment support system. The blood tumor data acquisition and in-hospital and out-of-hospital integrated diagnosis and treatment support system comprises a cloud follow-up visit platform, a medical management end system, a data transmission system and a user end system, wherein thecloud follow-up visit platform is connected with the medical management system and the client system through the data transmission system; and the medical management system is connected with the client system through the data transmission system. The blood tumor data acquisition and in-hospital and out-of-hospital integrated diagnosis and treatment support system has the advantages that the systemestablishes a data analysis system based on index data to form a rigorous diagnosis and treatment scheme; doctor-patient joint interaction is achieved, and the doctor-patient trust degree is improved; the intelligent reminding service effectively enhances the diagnosis and treatment executive force; professional follow-up visit management effectively improves data collection efficiency, accuracyand availability, promotes national blood disease prevention and management quality, and improves national health quality of China; and change rules of patients and diseases are comprehensively understood through data, and experience is summarized, and a treatment scheme is adjusted or improved, and the treatment effect and extrahospital life quality of the patients are improved, and development of modern medicine of the hematology department is promoted.